<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82209">
  <stage>Registered</stage>
  <submitdate>14/08/2007</submitdate>
  <approvaldate>22/08/2007</approvaldate>
  <actrnumber>ACTRN12607000426482</actrnumber>
  <trial_identification>
    <studytitle>Selective nerve blocks to relieve pain of knee arthritis</studytitle>
    <scientifictitle>Selective nerve blocks to relieve pain of knee arthritis</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>knee osteoarthritis</healthcondition>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Osteoarthritis</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Double blind Randomised selective subcutaneous nerve blocks with local anaesthetic or normal saline in 0.5mL aliquots upto maximum 10 mL for complex knee pain in patients awating knee replacement. The trial involves 1 set of injections with the study drug and upto 2 sets of injections with open label 1% lignocaine to determine if pain can be relieved and the duration of pain relief.</interventions>
    <comparator>Normal saline control</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Visual Analgue Pain Scale (VAPS) 0-100 pain score</outcome>
      <timepoint>Baseline, 2 hour, 1 week, 1, 3, 6 months post treatment</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Brief Pain Inventory</outcome>
      <timepoint>Baseline, 2 hour, 1 week, 1, 3, 6 months post treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Medical Outcome Short Form (36) Health Survey (MOS SF36)</outcome>
      <timepoint>Baseline, 1 week, 1, 3, 6 months post treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Knee osteoarthritis outcome score (KOOS)</outcome>
      <timepoint>Baseline, 1 week, 1, 3, 6 months post treatment</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Waiting list patients with painful knee(s) rated &gt;=5/10 on Verbal Rating Scale (VRS)awaiting knee arthroplasty</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>-2147483648</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Subject on waiting list for a revision knee replacement, has terminal cancer or is unable to communicate or refuses to participate.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>sealed opaque envelopes</concealment>
    <sequence>Simple randomisation by using a randomisation table created by computer software.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Other</assignment>
    <designfeatures>Block 1: DB random allocation to lignocaine 1% or N-saline injection;
Block 2: Open label 1% lignocaine injection if pain persists 1 week later;
Block 3: option of 2nd open label 1% lignocaine.
Patients obtaining short term pain relief will be offered</designfeatures>
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>8/11/2007</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>30</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up continuing</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Dr Murray Taverner</primarysponsorname>
    <primarysponsoraddress>Frankston Hospital
PO Box 52
Frankston, 3199</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Frankston Hospital</fundingname>
      <fundingaddress>Frankston Hospital
PO Box 52
Frankston, 3199</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Dr Terence Loughnan</sponsorname>
      <sponsoraddress>Frankston Hospital
PO Box 52
Frankston, 3199</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Dr Ashley Webb</othercollaboratorname>
      <othercollaboratoraddress>Frankston Hospital
PO Box 52
Frankston, 3199</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Knee pain is a common problem with 19-23% prevalence in people aged 40 and over. Frankston hospital has 138 patients awaiting knee replacement and a waiting time exceeding 18 months. Preliminary work suggest patient with anterior, medial and lateral compartment knee pain who have not had open knee surgery may obtain good but temporary pain relief and functional improvement from selectively anaesthetising the cutaneous nerves supplying the knee joint. This study seeks to validate the injection technique, determine which nerves need to be injected and which patients, pain patterns and pathology may benefit from this treatment or may benefit from a follow-on study of pulse radiofrequency treatment to these nerves.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Frankston hospital</ethicname>
      <ethicaddress>Frankston Hospital
PO Box 52
Frankston, 3199</ethicaddress>
      <ethicapprovaldate>7/08/2006</ethicapprovaldate>
      <hrec>2006-22</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Murray Taverner</name>
      <address>Frankston Hospital
PO Box 52
Frankston, 3199</address>
      <phone>03 9784 7445</phone>
      <fax>03 9784 7441</fax>
      <email>mtaverner@phcn.vic.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Murray Taverner</name>
      <address>Frankston Hospital
PO Box 52
Frankston, 3199</address>
      <phone>03 9784 7445</phone>
      <fax>03 9784 7441</fax>
      <email>mtaverner@phcn.vic.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Murray Taverner</name>
      <address>Frankston Hospital
PO Box 52
Frankston, 3199</address>
      <phone>03 9784 7445</phone>
      <fax>03 9784 7441</fax>
      <email>mtaverner@phcn.vic.gov.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>